Lisata Therapeutics, Inc. (NASDAQ:LSTA – Free Report) – HC Wainwright increased their Q3 2025 EPS estimates for shares of Lisata Therapeutics in a report issued on Thursday, August 21st. HC Wainwright analyst J. Pantginis now anticipates that the company will earn ($0.56) per share for the quarter, up from their previous forecast of ($0.67). HC Wainwright currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for Lisata Therapeutics’ current full-year earnings is ($2.66) per share. HC Wainwright also issued estimates for Lisata Therapeutics’ Q4 2025 earnings at ($0.74) EPS, FY2025 earnings at ($2.40) EPS, FY2026 earnings at ($1.09) EPS, FY2027 earnings at ($1.16) EPS and FY2028 earnings at ($0.98) EPS.
Separately, Brookline Capital Management raised their price objective on shares of Lisata Therapeutics from $20.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, July 15th. Two equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $23.50.
Lisata Therapeutics Trading Up 4.9%
Lisata Therapeutics stock opened at $2.59 on Monday. Lisata Therapeutics has a 12-month low of $1.87 and a 12-month high of $4.20. The stock has a market cap of $22.69 million, a P/E ratio of -1.16 and a beta of 0.93. The company has a 50-day moving average price of $2.62 and a 200 day moving average price of $2.46.
Lisata Therapeutics (NASDAQ:LSTA – Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.11. The firm had revenue of $0.07 million for the quarter.
Institutional Investors Weigh In On Lisata Therapeutics
A number of large investors have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP grew its stake in Lisata Therapeutics by 45.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 25,226 shares of the company’s stock valued at $75,000 after acquiring an additional 7,886 shares during the last quarter. Cerity Partners LLC acquired a new stake in Lisata Therapeutics in the 2nd quarter valued at about $32,000. Finally, Citadel Advisors LLC acquired a new stake in Lisata Therapeutics in the 4th quarter valued at about $69,000. 8.94% of the stock is owned by institutional investors and hedge funds.
Lisata Therapeutics Company Profile
Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.
See Also
- Five stocks we like better than Lisata Therapeutics
- What is a Death Cross in Stocks?
- Costco and Ross: 2 Ways to Play the Consumer Divide
- What is a Low P/E Ratio and What Does it Tell Investors?
- Is Paramount Skydance a Buy Post-Merger, Short Squeeze?
- Comparing and Trading High PE Ratio Stocks
- V2X Stock: Defense Underdog Riding a $4.3B Air Force Contract
Receive News & Ratings for Lisata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lisata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
